The global cell surface marker detection market is projected to generate USD 9,427.4 million revenue by 2030, advancing at a CAGR of 8.1% during 2024–2030. This can be ascribed to the increasing demand for precision medicine, rising adoption of in vitro diagnostics, and technological advances leading to increased throughput and level of automation.
The number of diabetic patients increased from over 105 million in 1980 to over 420 million in 2014, and approximately 600 million people are expected to suffer from diabetes by 2035. In 2017, around 430 million people aged 20–79 years had diabetes, and this population is projected to reach around 630 million by 2045, globally.
The surge in the number of diabetic patients is not only restricted to developed countries but is being witnessed in emerging economies as well. For instance, the number of diabetic patients in India will reach more than 120 million by 2040. This rise in the diabetes incidence over time is expected to fuel the demand of cell surface marker detectors for ascertaining the presence and concentration of T lymphocytes, which play a key role in initiating the onset of diabetes by destroying pancreatic β-cells.
Flow cytometry instruments held the largest share, of 35%, in 2023. Flow cytometry is a technique that runs tens of thousands of particles every second and defines subpopulations using multiparameter analysis tools. It is used in clinics and hospitals to provide diagnostic information on cancer cells, inflammatory conditions, and a variety of syndromes. Further, it is used as a core research tool in the biotechnology and pharmaceutical industries, as well as research centers and universities. This is because it is one of the best technologies for analyzing single cells.
Moreover, hematology analyzers held a significant share in 2022, mainly because they are used for both specialized and routine diagnostic testing. They allow medical experts to make an accurate and rapid diagnosis of a diversity of diseases and advise suitable treatments.
Hematology analysis also offers cost-effectiveness and high performance. These systems are reliable and accurate, which allows them to be used for an extensive range of procedures. This allows laboratories to perform medical tests without investing heavily in expensive equipment. Generally, the consumption of reagents and samples is low because of the instruments’ efficiency.
Moreover, the European cell surface marker detection market held a significant share in 2023. This is mainly because of the increasing geriatric population, rising incidence of chronic diseases, and growing funding for life science research. For instance, in 2020, in Germany, more than USD 105 billion were invested in R&D.
Various institutions and organizations contribute the funding. Moreover, the public sector offers over 30% of the investment for R&D in the country. Additionally, business enterprises contribute over USD 70 billion in R&D funding each year.
Moreover, in the U.K., the prevalence of chronic diseases, such as CVDs and diabetes, is on the rise. The number of deaths due to heart and circulatory diseases before 75 years of age is increasing for the first time in half a century. Heart diseases already cause a quarter of all deaths in the country, which is more than 1.6 million deaths each year, an average of 460 deaths each day, or one every three minutes.
Major players operating in the cell surface marker detection market include Abbott Laboratories, Becton, Dickinson and Company, Nihon Kohden Corporation, Thermo Fisher Scientific Inc., Sysmex Corporation, Janssen Diagnostics Inc., Grifols SA, Siemens Healthcare, BioRad Laboratories Inc., and F. Hoffmann-La Roche Ltd.